NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance

Author(s): Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, et al.

Abstract

Insulin resistance is associated with chronic low-grade inflammation in vivo, largely mediated by activated innate immune cells. Cytokines and pathogen-derived ligands of surface toll-like receptors can directly cause insulin resistance in muscle cells. However, it is not known if intracellular pathogen sensors can, on their own, provoke insulin resistance. Here, we show that the cytosolic pattern recognition receptors nucleotide-binding oligomerization domain-containing protein (NOD)1 and NOD2 are expressed in immune and metabolic tissues and hypothesize that their activation in muscle cells would result in cell-autonomous responses leading to insulin resistance. Bacterial peptidoglycan motifs that selectively activate NOD2 were directly administered to L6- GLUT4myc myotubes in culture. Within 3 h, insulin resistance arose, characterized by reductions in each insulin-stimulated glucose uptake, GLUT4 translocation, Akt Ser(473) phosphorylation, and insulin receptor substrate 1 tyrosine phosphorylation. Muscle cell-autonomous responses to NOD2 ligand included activation of the stress/inflammation markers c-Jun N-terminal kinase, ERK1/2, p38 MAPK, degradation of inhibitor of κBα, and production of proinflammatory cytokines. These results show that NOD2 alone is capable of acutely inducing insulin resistance within muscle cells, possibly by activating endogenous inflammatory signals and/or through cytokine production, curbing upstream insulin signals. NOD2 is hence a new inflammation target connected to insulin resistance, and this link occurs without the need of additional contributing cell types. This study provides supporting evidence for the integration of innate immune and metabolic responses through the involvement of NOD proteins and suggests the possible participation of cell autonomous immune responses in the development of insulin resistance in skeletal muscle, the major depot for postprandial glucose utilization.

Similar Articles

Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review

Author(s): Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, et al.

Gut microbiota and non-alcoholic fatty liver disease: new insights

Author(s): Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Author(s): Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al.

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Role of gut microbiota: obesity and NAFLD

Author(s): Gangarapu V, Yıldız K, Ince AT, Baysal B

Hepatic histology in obese patients undergoing bariatric surgery

Author(s): Machado M, Marques-Vidal P, Cortez-Pinto H

Gut microbiota and liver disease

Author(s): Goel A, Gupta M, Aggarwal R

An obesity-associated gut microbiome with increased capacity for energy harvest

Author(s): Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al.

Obesity alters gut microbial ecology

Author(s): Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, et al.

Microbial ecology: human gut microbes associated with obesity

Author(s): Ley RE, Turnbaugh PJ, Klein S, Gordon JI

Microbiota and SCFA in lean and overweight healthy subjects

Author(s): Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, et al.

Human colonic microbiota associated with diet, obesity and weight loss

Author(s): Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al.

Enterotypes of the human gut microbiome

Author(s): Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al.

The gut microbiota as an environmental factor that regulates fat storage

Author(s): Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al.

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

Author(s): Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI

Human gut microbiota in obesity and after gastric bypass

Author(s): Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, et al.

The gut microbiota, obesity and insulin resistance

Author(s): Shen J, Obin MS, Zhao L

Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice

Author(s): Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, et al.

The role of gut microbiota on insulin resistance

Author(s): Caricilli AM, Saad MJ

Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance

Author(s): Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al.

Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis

Author(s): Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, et al.

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

Author(s): Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al.

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

Author(s): Rivera CA, Gaskin L, Allman M, Pang J, Brady K, et al.

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5

Author(s): Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, et al.

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis

Author(s): Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al.

A functional role for Nlrp6 in intestinal inflammation and tumorigenesis

Author(s): Chen GY, Liu M, Wang F, Bertin J, Núñez G

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Author(s): Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al.

NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion

Author(s): Wlodarska M, Thaiss CA2, Nowarski R3, Henao-Mejia J3, Zhang JP4, et al.

NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens

Author(s): Anand PK, Malireddi RK, Lukens JR, Vogel P, Bertin J, et al.

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

Author(s): Bergheim I, Weber S, Vos M, Krämer S, Volynets V, et al.

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

Author(s): Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB

Review article: prebiotics in the gastrointestinal tract

Author(s): Macfarlane S, Macfarlane GT, Cummings JH

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis

Author(s): Ma YY, Li L, Yu CH, Shen Z, Chen LH, et al.